Elosulfase Alfa (Vimizim)

Vimizim (elosulfase alfa) is covered only for the FDA‑approved treatment of Mucopolysaccharidosis type IVA (Morquio A) and off‑label uses are excluded. Coverage requires patients be ≥5 years with diagnosis confirmed by galactose‑6‑sulfatase enzyme assay or genetic testing, is authorized for up to 12 months (reauthorization needed), and administration precautions include premedication for hypersensitivity and delaying infusion for acute febrile/respiratory illness because of anaphylaxis risk.

"Treatment of individuals with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.